(12) UK Patent Application (19) GB (11) 2 130 588 A

(21) Application No 8329173
(22) Date of filing 1 Nov 1983
(30) Priority data
(31) 8231278
(32) 2 Nov 1982
(33) United Kingdom (GB)
(43) Application published
6 Jun 1984
(51) INT CL³
C07J 41/00
A61K 31/58
(52) Domestic classification
C2U 3 4A2A 4C1 4C4A
4D1 4N1 8A1
U1S 2412 2413 2415 C2U
(56) Documents cited
GB A 2010278
GB 1604664
GB 1123770
US 3296255
"The Theory and Practice
of Industrial Pharmacy"
by L. Lachman, H.A.
Lieberman & J.L. Kanig,
2nd edition (Lea &
Febiger, 1976), pp. 101-3,
section headed "Effective
Surface Area"
"Steroids" vol 32 (1978)
pp257-267
(58) Field of search
C2U
(71) Applicant
Sterwin AG,
(Switzerland),
Zeughausgasse 9,
CH-6300 Zug,
Switzerland.
(72) Inventor
George Margetts
(74) Agent and/or Address for
Service
Sanderson & Co.,
97 High Street,
Colchester,
Essex CO1 1TH.

(54) **Micronised 2α-cyano-4α,5α-epoxy-3-oxo steroids**

(57) The bioavailability of 2α-cyano-4α,5α-epoxy-3-oxo steroids, e.g. trilostane, is improved by micronising them to particles having a mean equivalent sphere volume diameter of less than 20 μm, at least 95% of the particles having a particle size of less than 50 μm.

GB 2 130 588 A

Formulae in the printed specification were reproduced from drawings submitted after the date of filing, in accordance with Rule 20(14) of the Patents Rules 1982.

SPECIFICATION

Steroid compounds

5 The present invention relates to certain steroid compounds, and in particular to pharmaceutical   5
compositions comprising an active ingredient selected from those steroid compounds, in which the particle
size of the active compound is controlled in order to obtain a higher and more acceptable level of *in vivo*
activity.
　　　The present invention is concerned specifically with 2α-cyano-4α,5α-epoxyandrostan-17β-ol-3-one having
10 the formula: 10

(I)

20   20

　　　The above compound of formula (I) has the common name "trilostane" and is described, for example, in
British Patent Specification No. 1,123,770 and in U.S. Patent Specification No. 3,296,295. These earlier
Specifications describe the adrenocortical inhibiting properties of trilostane and related compounds, as does
25 the article by Neumann et al in Journal of Medicinal Chemistry, *13*, 948 (1970).   25
　　　It is currently proposed to use trilostane as an abortifacient, and also, more importantly, in the treatment of
Cushing's Syndrome and Conn's Syndrome. Cushing's Syndrome is due to an increased secretion of
hydrocortisone-type steroids, and Conn's Syndrome is due to an adenoma of the glomerulosa cells of the
adrenal cortex, with which there is an increase in aldosterone secretion. Hypertension is always present in
30 Conn's Syndrome.   30
　　　It is believed that trilostane is of value in the above treatments due to its inability to act as an
anti-hypertensive, especially in those patients where hyptersion is associated with high aldosterone and low
renin; low aldosterone and low renin; high aldosterone and high renin; and low aldosterone and high renin.
　　　Prior to the present invention, the use of trilostane and related compounds met with unsatifactory results
35 because previous formulations gave variable absorption characteristics and unpredictable blood levels.   35
Thus, previous formulations of trilostane have been found to be unreliable in the treatment or control of
symptoms in those conditions mentioned above due to variations in availability of trilostane *in vivo*.
　　　We have now found that by processing raw trilostane and related compounds to bring their particle size
within a particular narrow range, pharmaceutical compositions can be prepared which exhibit for their active
40 ingredient improved absorption characteristics and which can avoid or substantially avoid the unsatisfactory 40
results given by previous formulations. Despite the fact that in *in vitro* testing products containing batches of
trilostane of differing particle sizes could not be differentiated in respect of their dissolution or release
properties, control of particle size has been shown to produce, as described in more detail below, a
significant improvement in plasma concentration *in vivo*.
45　　　Accordingly, the present invention provides, in particular for use in preparing pharmaceutical composi-   45
tions having improved absorption characteristics, a 2α-cyano-4α,5α-epoxy-3-oxo-steroid compound having
a basic ring structure of the general formula:

50   50

(II)

55   55

the compound being in particulate form and consisting of particles having a mean equivalent sphere volume
diameter of less than about 20μm, at least 95% of the particles having a particle size of less than about 50
60 μm.   50
　　　In one aspect of the invention, the particulate compound may be a compound of the above formula II of the
kind described in British Patent Specification No. 1,123,770, that is to say a 2α-cyano-4α,5α-epoxy-3-oxo-
steroid in which the steroid moiety has from 19 to 23 carbon atoms exclusive of ester radicals.
　　　Alternatively, in another aspect of the invention the particulate compound may be a compound of the
65 above formula II of the kind described in British Patent Specification No. 2,010,278A, that is to say a   55

2α-cyano-4α,5α-epoxy-3-oxo-steroid having the general formula:

(III)

wherein R is hydrogen or methyl;
R' is hydroxy or lower-alkanoyloxy;
R" is hydrogen, lower-alkyl, lower-alkenyl or lower-alkynyl;
or R' or R" together represent oxo or ethylenedioxy;
R''' is hydrogen or methyl;
or 3-enol lower-alkanoate esters thereof;
with the proviso that when R is hydrogen, R''' is α-methyl, and when R is methyl, R''' is hydrogen or β-methyl,
which compounds are disclosed as being useful as interceptive agents, that is in disrupting pregnancy when
administered to pregnant female mammals.
    Preferably, the compound of the invention is a compound of the general formula:

(IV)

wherein R is hydrogen or methyl and R" is hydrogen or lower alkyl, especially methyl.
    Most preferably the compound of the invention is trilostane, i.e. a compound of formula (IV) wherein R and
R" are both hydrogen; or a compound of formula (IV) wherein R and R" are both methyl. It is believed the
invention is particularly applicable to those two specific compounds, and in particular the former compound,
trilostane.
    Preferably, the particulate compound of the invention consists of particles having a mean equivalent
sphere volume diameter of about 12μm or less, with a preferred lower limit being about 4 to about 5. More
preferably, the mean equivalent sphere volume diameter of the particles should be about 10μm or less e.g.
from about 5 to about 10μm, and still more preferably about 5μm, at least 95% particles always having a
particle size of less than 50μm.
    (It will of course be understood by those familiar with comminution process techniques that the limit set
on the size of 95% or more of the particles is a subsidiary limitation necessary additionally to distinguish the
particulate compounds of the invention from those exhibiting a broader size distribution, because of the
wide variation in size encountered in all powders reduced in size by a process of comminution or particle size
reduction, for example, by milling utilising a variety of kinds of milling equipment now available, for
example, hammer, pin or fluid energy mills.)
    The invention also provides pharmaceutical compositions comprising the said particulate compound of
the invention and one or more pharmaceutically-acceptable excipients or carriers.
Such excipients or carriers may be solid, semi-solid or liquid as appropriate to the pharmaceutical form
chosen, and may include a wide range of organic and inorganic solids, semi-solids and aqueous and
non-aqueous liquids. Of these there may be used, for example, talc, gum arabic, starch, lactose, magnesium
stearate or fatty substances of animal or vegetable origin such as cocoa butter, lanolin derivatives, paraffin
derivatives or glycols. These excipients or carriers may be compounded with one or more wetting,
dispersing or emulsifying agents and/or one or more preservatives as desired. Thus, the compositions of the
invention may be presented as a tablet, capsule, granulate for suspension, cream, ointment, suppository or
suspension.
    Preferably the composition of the invention includes a solid excipient or carrier with which the said
particulate compound of formua (II) is mixed, for example, starch, lactose and/or magnesium stearate.
More preferably, the composition is presented as a tablet or in an encapsulated form, the particulate

compound of formula (II), together with any excipient or carrier being filled into the shell of a capsule. Preferably, the capsule contains active compound and diluent in a ratio of about 1:3.

Typically, the composition of the invention when in unit dosage form may comprise a unit dose of from about 50 to about 250 mg of the compound of formula (II), for example, about 60 mg, about 120 mg and
5 about 240 mg, and more preferably about 50 to about 120 mg.   5

Preferably the particulate compound of formula (II) is also one in which the specific surface area is at least about $2m^2 g^{-1}$ e.g. 2 to $4 m^2 g^{-1}$.

The invention also includes a method of treating a steroid compound having a basic ring structure of the general formula (II) shown above, which method comprises processing the raw steroid compound in a
10 treatment which reduces its particle size so as to produce a compound in particulate form and consisting of   10
particles having a mean equivalent sphere volume diameter of less than about 20 μm, at least 95% of the particles having a particle size of less than about 50 m.

In preparing the particulate compound of the invention a compound of formula (II), in its raw state, is first characterised for size using an instrument adapted to measure equivalent sphere volume diameter, that is to
15 say a Coulter Counter. Typically a representative sample of a compound of formula (IV) where R and R"=H   15
would be expected to comprise in its raw state particles having a mean equivalent sphere volume diameter of about 40 μm and with a broad size distribution.

After being characterised for size in its raw state, the raw compound is then milled, preferably using a fluid energy (air) mill, under suitable conditions e.g. of air pressure and feed rate, to bring the particle size value
20 within the above-mentioned limits according to the invention. The efficiency of the milling is checked by   20
sampling using a Coulter Counter and the final particle size is checked in a similar manner. If a first pass through the mill does not produce the required size spectrum, then one or more further passes are effected.

The compound of formula (II) in its particulate form within the above-mentioned limits according to the invention may then be mixed with an excipient or carrier as necessary and, for example, filled into capsules.
25 Thus, for example, the particulate compound may be mixed with maize starch and lactose, granulated with   25
water, dried, terminally blended with magnesium stearate, and filled into capsules.

Because the particles obtained by milling or other particle size reduction techniques are irregular in shape, it is necessary to characterise them not by measurement of an actual size such as thickness or diameter, but by measurement of a property of the particles which is related to the same property when possessed by a
30 theoretical spherical particle. The particles are thus allocated an "equivalent sphere diameter".   30

The values found from characterising a large number of "unknown" particles can be plotted number vs. diameter or in other methods weight vs. diameter, usually adopting percentage oversize values for number or weight. This gives a characteristics curve representing size distribution of the sample, i.e. a cumulative percentage oversize distribution curve. Values from this can be read off directly or plotted on log-probability
35 paper to give an approximately straight line. The mean equivalent sphere volume diameter is the 50%   35
oversize value and the slope of the line is related to the standard deviation (s.d.) of the distribution. For convenience this may be calculated from the values at 84.1% and 15.9% oversize together with the mean equivalent sphere volume diameter thus:

40   40

$$s.d. = \frac{\text{Mean equivalent sphere volume diameter} \; (=50\% \; \text{oversize})}{\text{Diameter at 84.1\% oversize}}$$

or

45   45

$$s.d. = \frac{\text{Diameter at 15.9\% oversize}}{\text{Mean equivalent sphere volume diameter} \; (=50\% \; \text{oversize})}$$

50   50
The above applies for a log normal distribution, which may acceptably be assumed for milled powder samples. Typically, a particulate compound according to the invention will give a standard deviation of about 2μm.

The mean equivalent sphere volume diameter found is thus a statistical representation of a theoretical
55 particle having the same property as the "unknown" particles.   55

As indicated above the mean equivalent sphere volume diameter of the particles of the milled compound of formula (II) may be evaluated using a Coulter Counter. Using such an instrument values for a suspension of the particles of unknown size may be obtained and the Counter may be calibrated using a standard suspension of latex particles within the size range expected for the particles of unknown size. In the case of
60 standard latex particles values of standard deviation are extremely small because of the "sieve cut" nature   60
or very uniform particle size.

Following is a description by way of example of the preparation of compositions in accordance with the invention. In all of the Examples the trilostane was prepared from a raw form using a fluid energy (air) mill and consisted of particles having a mean equivalent sphere volume diameter of about 10μm, at least 95% of
65 the particles having a particle size of less than about 50μm. The particle size of the reduced trilostane was   65

measured as follows:

First a small sample was checked under a microscope and a visual assessment made both of the size of the particles against a standard calibration scale, e.g. say predominantly about 10μm, and of the uniformity of particle size. These visual assessments indicating acceptable parameters, that is most particles being within
5 the desired size range and size distribution, a further sample of the reduced material was subjected to particle size measurement using a Coulter Counter TAII by the procedure given below. Alternatively, if the small sample visual check gave an estimated size or size distribution outside the desired specification, the milling conditions were adjusted.

The Coulter Counter particle size measurement was effected on a 5 mg sample of the reduced material, the
10 sample being suspended in approximately 100 ml of electrolyte, for example, Isoton II. Prior to the sample suspension the electrolyte was saturated with micronised material, the pH of the resultant solution was adjusted to about 3.5, and the solution was filtered through a 0.22μm microporous membrane filter to provide the necessary particle-free suspending electrolyte.

The electrolyte solution contained one drop of Coulter dispersant and dispersion was effected using an
15 ultrasonic bath treatment for approximately one minute. The suspension was then diluted to approximately 200 ml with Isoton II and treated again in the ultrasonic bath for approximately one minute. The acceptability of the dispersion concentration was checked using a preset count of 70,000 particles with an aperture of 140μm (satisfactory for 5 to 10μm mean equivalent sphere volume diameter particles) to give a reading of less than 10% on the calibration scale. (In any size analysis technique, because the particles are of differing
20 size, it is necessary to characterise a large number for statistical accuracy of the result. The value of 70,000 is that chosen in this case.

The tube aperture in the Coulter Counter is chosen depending on the expected particle size values. Greatest result accuracy is obtained when the particle diameters are from 4 to 40% of the aperture size to avoid false counts and disturbance. A calibration scale of 10% is a Coulter Electronics recommendation of no
25 significance to the size).

Within ten minutes of the preparation of the dispersion, duplicate ciounts were performed. Duplicate counts are effected as a minimum check a) to produce more reliable measurements and b) to check that equipment sampling of the suspended material has been reproducible i.e. the suspension has not settled.

The checked results were automatically recorded and displayed graphically to give a cumulative
30 percentage oversize versus size characteristic curve for the sample. From this, the mean equivalent sphere volume diameter value was derived (50% oversize value) together with the standard deviation of the distribution calculated as described above.

The standard deviation was the expected value of approximately 2.0μm, the limit being between about 1.8μm and about 2.5μm on ten batches.
35 The Coulter Counter was calibrated as follows:

A suspension of standard Coulter Electronics latex particles of stated mean diameter of 13.7μm was treated as above using an aperture and equipment settings as described. The mean value derived was between 12.5 and 14.5μm when the Counter was correctly calibrated. Compositions were then prepared as follows:
40

Example 1

Capsules:	Formulations	60mg	120mg
	Trilostane	60 mg	120 mg
	Lactose	86 mg	172 mg
	Maize starch	86.65 mg	173.3 mg
	Magnesium stearate	2.35 mg	4.7 mg
		235 mg	470 mg

Preparation

These formulations are prepared by either conventional dry blending techniques or more preferably conventional wet granulation techniques. Encapsulation is effected by means of convention equipment.

Example 2

Tablets	Formulations	60 mg	120 mg	240 mg
	Trilostane	60 mg	120 mg	240 mg
	Lactose	80 mg	160 mg	320 mg
	Maize starch	85 mg	170 mg	340 mg
	Magnesium stearate	2 mg	4 mg	8 mg
		227 mg	454 mg	908 mg

Preparation
   The powders are granulated by means of conventional wet granulation techniques. The tablets are compressed using conventional compression equipment to tablet or caplet form.

Example 3

Suppositories	Formulations	60 mg	120 mg	240 mg
	Trilostane	60 mg	120 mg	240 mg
	Suppository base	qs	qs	qs

Preparation
   The suppositories are prepared from a suitable suppository base (e.g. Suppocire, Witepsol, Novata, etc.) using conventional poured melt techniques or cold compression.

Example 4

Ointment	Formulations	1%	2.5%	5%
	Trilostane	1%	2.5%	5%
	Ointment base	to 100%	to 100%	to 100%

Preparation .
   The ointments are prepared by incorporating the trilostane into a suitable pre-prepared ointment base (e.g. white soft paraffin).

Example 5

Cream	Formulation	1%	2.5%	5%
	Trilostane	1%	2.5%	5%
	Cream base	to 100%	to 100%	to 100%

Preparation
   The creams are prepared by incorporating the trilostane into a suitable pre-prepared cream base (e.g. aqueous cream B.P.)

Example 6

Suspension	Formulations	1.2%	2.4%	4.8%
	Trilostane	1.2%	2.4%	4.8%
	Citric acid (anhydrous) BP	0.237%	0.237%	0.237%
	Sorbitol solution BPC	20%	20%	20%
	Cetomacrogol 1000 BPC	0.09%	0.09%	0.09%
	Sodium phosphate BP	0.63%	0.63%	0.63%
	Sodium carboxy-methyl cellulose	0.20%	0.20%	0.20%
	Veegum K	1.00%	1.00%	1.00%
	Flavour	qs	qs	qs
	Preservative	qs	qs	qs
	Purified water	to 100%	to 100%	to 100%

Preparation

The suspensions are prepared by conventional manufacturing techniques having regard to the processing properties of the ingredients. Finally, each suspension is passed through a homogeniser.

Bioavailability test:

60 mg capsules were prepared as described in Example 1 by wet granulation techniques using batches of trilostane comprising (i) particles having a mean equivalent sphere volume diameter of about $10\mu m$ (at least about 95% of the particles having a particle size of less than about $50\mu m$), (ii) particles of mean equivalent sphere volume diameter of about $45\mu m$, and (iii) particles of mean equivalent sphere volume diameter greater than $100\mu m$.

In a three part double blind cross-over study on eight volunteers, each volunteer received a dosage of 120 mg of trilostane (2 × 60 mg capsules) on an empty stomach with 50 ml of tap water. Blood samples (8 ml) were taken pre-medication and at 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0 and 24.0 hours and assayed for plasma levels of trilostane and trilostane metabolite. Plasma concentrations were processed by a computer programme giving maximum concentration in plasma (C_{max}) and time taken to reach this maximum (T_{max}) by inspection. Values for the area under the curve of concentration against time over the time span 0 to t (AUC_0^t - where t is time) were then calculated using the tapezoid rule and statistical analysis was carried out using the Students paired t-test.

In most cases, plasma levels could not be detected at 24 hours and consequently AUC_0^{24} could be used to assess the extent of absorption. The following Table I sets out AUC_0^{24} values (mg.m^{-1}.h) for trilostane and 17-keto metabolite.

TABLE I

Particle size	10 µm	45 µm	100 µm
Trilostane AUC_0^{24}	1.6	0.6	0.2
Metabolite AUC_0^{24}	5.0	2.7	1.3

As can be seen from the above results, plasma trilostane and metabolite concentration are dependent on the particle size of trilostane used, the smallest particle size material, i.e. that according to the invention, giving rise to the highest plasma concentrations. Plasma metabolite concentrations followed the time course of trilostane concentrations very closely but at a level of 2 to 3 times higher. In addition, the ratio of Metabolite AUC_0^{24} to Trilostane AUC_0^{24} for the $10\mu m$, $45\mu m$ and $100\mu m$ materials is respectively 3.1, 4.5 and 6.5.

Thus, the lower AUC_0^{24} values for the larger particle size capsules indicate that the extent of absorption from those capsules was reduced. Furthermore, with the smallest particle size material there is a highly favourable ratio of trilostane active material to trilostane metabolite.

Accordingly, the results given above indicate clearly that the particle size of trilostane used in the formulations had a very pronounced influence on the availability of trilostane in plasma. The capsules containing 10μm material resulted both in high plasma trilostane and metabolite concentrations, as well as a favourable ratio of trilostane to metabolite. However, an increase in particle size of trilostane to approximately 45μm and then to greater than 100μm resulted in successive reductions in the plasma concentration levels, as well as in significant increase in the ratio of metabolite to active material.

In our co-pending British Patent Application No. 83-28929 there is described and claimed a method of preparing a compound, for example, of the above formula III in which, in particular, R is methyl, R' is hydroxy and R" is methyl, having a reduced particle size inter alia as defined herein, which method comprises dissolving the compound in an organic solvent, preferably dimethylformamide, precipitating the compound by mixing a non-solvent for the compound, preferably water, with the said solution, and controlling the mixing conditions to produce a precipitate having the desired reduced particle size.

It is to be understood that in preparing a compound of the formula III in accordance with the present invention in which, in particular, R is methyl, R' is hydroxy and R" is methyl, it is preferred to employ the method of our co-pending Application.

CLAIMS

1. A 2α-cyano-4α,5α-epoxy-3-oxo-steroid compound having a basic ring structure of the general formula:

(II)

the compound being in particulate form and consisting of particles having a mean equivalent sphere volume diameter of less than about 20 μm, at least 95% of the particles having a particle size of less than about 50 μm.

2. A particulate compound according to claim 1, in which the steroid moiety has from 19 to 23 carbon atoms exclusive of ester radicals.

3. A particulate compound according to claim 1 of the general formula:

(III)

wherein R is hydrogen or methyl;
R' is hydroxy or lower-alkanoyloxy;
R" is hydrogen, lower-alkyl, lower-alkenyl or lower-alkynyl;
or R' or R" together represent oxo or ethylenedioxy;
R''' is hydrogen or methyl;
or 3-enol lower-alkanoate esters thereof;
with the proviso that when R is hydrogen, R''' is α-methyl, and when R is methyl, R''' is hydrogen or β-methyl.

4. A particulate compound according to claim 1 of the general formula:

(IV)

15 wherein R is hydrogen or methyl and R″ is hydrogen or lower alkyl.

     5. A particulate compound according to claim 4, wherein R and R″ are hydrogen.

     6. A particulate compound according to claim 4, wherein R and R″ are methyl.

     7. A particulate compound according to any one of the preceding claims, wherein the particles have a mean equivalent sphere volume diameter of about 12 μm or less.

20   8. A particulate compound according to claim 7, wherein the particles have a mean equivalent sphere volume diameter of about 10 μm or less.

     9. A particulate compound according to claim 8, wherein the mean equivalent sphere volume diameter of the particles is from about 5 to about 10 μm.

     10. A particulate compound according to any one of the preceding claims, wherein the mean equivalent

25 sphere volume diameter of the particles is about 5 μm.

     11. A particulate compound according to any one of the preceding claims, wherein its cumulative percentage oversize versus size characteristic curve exhibits a standard deviation of about 2 μm.

     12. A particulate compound according to any one of the preceding claims, wherein its specific surface area is about $2m^2 g^{-1}$ or higher.

30   13. A particulate compound according to any one of the preceding claims, wherein the mean equivalent sphere volume diameter is measured using a Coulter Counter as hereinbefore described specifically.

     14. For use in preparing pharmaceutical formulations exhibiting improved absorption characteristics for active ingredients and a higher active ingredient to metabolite ratio, a compound of the general formula (II) defined in claim 1 and according to any one of the preceding claims.

35   15. A method of treating a steroid compound having a basic ring structure of the general formula II shown in claim 1, which method comprises processing the raw steroid compound in a treatment which reduces its particle size so as to produce a compound in particulate form and comprising particles having a mean equivalent sphere volume diameter of less than about 20 μm, at least 95% of the particles having a particle size of less than about 50 μm.

40   16. A method according to claim 15, wherein the particle size reduction is effected by employing at least one pass in a fluid energy mill.

     17. A method according to claim 15 or claim 16, wherein the steroid compound is as defined in any one of claims 2 to 6 and/or the particle size is as defined in any one of claims 7 to 13.

     18. A method according to any one of claims 15 to 17 substantially as hereinbefore described specifically.

45   19. A pharmaceutical composition, which composition comprises a particulate compound according to any one of claims 1 to 13 and one or more pharmaceutically-acceptable excipients or carriers.

     20. A composition according to claim 19 in the form of a tablet, a capsule, a granulate for suspension, a cream, an ointment, a suppository or a suspension.

     21. A composition according to claim 20 in encapsulated form, the particulate compound of formula (II),

50 together with excipient or carrier being filled into the shell of a capsule, and the capsule containing active compound and diluent in a ratio of about 1:3.

     22. A composition according to any one of claims 19 to 21, in unit dosage form and comprising a unit dosage of from about 50 to about 250 mg of the compound of formula (II).

     23. A composition according to claim 19 and substantially as hereinbefore described with reference to

55 any one of the specific Examples.